SPRING 2026

Soliddd Shows Final “Baseball Cap” Prototype Before Mass Production

Soliddd has reached another key milestone. We have been working for many months on getting our core applications running on the Qualcomm XR2 Gen2 development kit, and everything is now working properly. This is the same chipset and roughly 90 percent of the code that will go into our final product.

We call this our “baseball cap” prototype. The development kit resides on a board too big to fit into our eventual eyeglasses design, so we have it supported by a cap. We 3D-printed the package that holds everything. Of course, this is in a much clunkier manner than the stylish design we’ll use once we can fit the chip set into eyeglasses, but the functionality of the system is the same.

Thank you all for your support! We are coming closer to real product!

Soliddd CEO Neal Weinstock to Speak at the ARVO 2026 Annual Meeting During the AMDF's "The Researcher's Role in a New Narrative for AMD" Presentation

At the ARVO 2026 Annual Meeting in Denver on May 5, the American Macular Degeneration Foundation (AMDF) is advancing a new narrative for macular degeneration — and it is proactive rather than reactive. Emerging from patients' experiences and advances in science, medicine, and technology, this new narrative replaces shock, despair, loss of independence and treatment burden with a new reality of empowerment and continued quality of life that is now within reach. 

Deploying this narrative at scale requires a broad coalition of AMD stakeholders: patients and caregivers, researchers, eyecare specialists and their training institutions, legislators, employers, nonprofits, and resource providers. This presentation will describe the framework for that effort, the role the research community plays within it, and will introduce, as one example, Soliddd’s new vision restoration technology that depends on at least some functional photoreceptors, and which is available for collaborative initiatives with clinicians and researchers. Lastly, findings from patient experiences with AI assistive technology will inform aspects of the New Narrative that bear on low vision services.

Speakers include

• Matthew Levine, Director of Grants, Advocacy and Partnerships, AMDF – A New Narrative for Age-Related Mascular Degeneration

• Neal Weinstock, CEO and Inventor, Solidddvision – A new technology that allows the brain to reconstruct vision.

• William Seiple, PhD, Chief Research Officer, The Lighthouse Guild – AI assistive tech and low vision rehab services.

Soliddd CEO Neal Weinstock Invited to Present to the Society for Information Display's Display Week 2026

During the SID's Display Week Symposium's Light Engineering and Visual Health session, Neal will be presenting an invited paper on The Natural Human Construction of Multiple Image Stereopsis From A Stanhope Lightfield Array to Correct Image Loss Due To Many Types Of Vision Issues. 

If you're attending Display Week at the Los Angeles Convention Center, the paper will be presented during the session in room 409AB on Thursday, May 7th between 8:30 AM - 10:00 AM.

The paper is scheduled to be released to the public on May 3rd on the SID website at www.displayweek.org.

Introducing Our Expanded Medical Advisory Board

We've expanded our Medical Advisory Board to include seven of the leading experts in their respective disciplines. These experts each brings a unique skillset to Soliddd to make sure that our technology benefits both the body and mind.

Michael S. Berlin, M.D., M.Sc., FAAO is the inventor of excimer laser technology. He is Founder & Director of Glaucoma Institute of Beverly Hills and EyeLight Innovations, Inc. He is a Professor of Clinical Ophthalmology, UCLA Stein Eye Institute and an active member of AGS, AAO, ASCRS, and ASLMS.

Georgia Crozier, O.D., M.S. is an optometrist, low vision specialist, and the Chief Medical Officer of Moore Eye Institute’s Low Vision Rehabilitation Center. She was the first optometrist selected by the federal government to receive a Masters of Science in Vision Rehabilitation. Dr. Crozier has lectured extensively and is a facilitator for low vision support groups.

Susan Malinowski, M.D. is a retinologist who is dedicated to education and advancements in vitreo-retinal disease. She is the author of numerous articles and lectures extensively, both nationally and internationally. She has completed original research to advance the development of low cost, alternative treatments for blinding eye diseases. She scored first in the nation on the Ophthalmology National Board Examination. 

William H. Seiple, Ph.D. is Chief Research Officer at Lighthouse Guild; Research Professor of Ophthalmology at NYU School of Medicine; Adjunct Faculty, Aging in Vision and Action Team, Institut de la Vision; and Visiting Professor at the Université Pierre-et-Marie-Curie, Paris, France.

Janet P. Szlyk, Ph.D. is President and CEO of The Chicago Lighthouse, and is a highly respected researcher and scientist in the field of low vision. In 2020, the National Federation of the Blind of Illinois honored Dr. Szlyk’s commitment to developing job opportunities for people who are blind or visually impaired with its prestigious Ilene O’Brien Memorial Award. 

Sonya Vieira, M.D. is a Psychiatrist and Psychoanalyst with over 20-years of experience caring for her patients. She is Board Certified in Adult Psychiatry and Fellowship-trained in Child & Adolescent Psychiatry. In her practice, she also offers psychoanalytically-informed psychotherapy with or without medication.

Bryan Wolynski, O.D., FAAO is the Chief of Vision Rehabilitation at Cleveland Sight Center, where he leads clinical and rehabilitation programs supporting people with vision loss across the lifespan. He has extensive experience in low vision rehabilitation and assistive technology integration into daily life. He has presented on these subjects nationally, internationally, and at the United Nations.

Testing Continues!

Our testing in New York City is continuing and we'll be in contact with as many people as we can who have signed up in order to schedule them. Plus, you can still sign up!

We are still particularly interested in testing people with loss of vision in some portion of their field, including those with

• Central cone dystrophy

• Cone rod dystrophy

• Glaucoma

• Macular degeneration and Stargardt disease, as before. Now, however, not only for central area vision loss, as we tested last year, but also for geographic atrophy.

• NAION

• Optic neuritis

• Retinal tears, blastomas, and other issues that block some portion of the visual field.

• Stroke

• And other retinopathy

To be considered for the program in New York City, please sign up here.